title: Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations.
abstract: We investigated the biological and clinical effects of naproxen sodium (NxS) in the short-term prophylaxis of pure menstrual migraine (PMM) in 25 women suffering from migraine without aura, occurring exclusively from 2 days before to 5 days after menstruation onset. Daily oral NxS (550 mg) from 7 days before menstruation to 7 days after menstruation onset was given for 3 menstrual cycles, and 5 days before menstruation to 5 days after menstruation onset over the next 3 menstrual cycles. In the month before initiation of treatment and in the third month of treatment, 6-keto-PGF1(alpha), TXB(2) and PGE(2) were measured in plasma before menstruation (day -2) and on the second day (day +2) after bleeding onset. In the 20 women analysed, 6-keto-PGF1(alpha) was 17% lower (p<0.0001) and TXB(2) was 30% lower (p<0.0001) on day -2 during treatment than the same day pretreatment; TXB(2) was also lower (p<0.02) on day +2 during treatment than day +2 pretreatment. The 6-keto-PGF1(alpha)/TXB(2) ratio was higher (p<0.01) on day -2 treatment than day -2 pretreatment. PGE(2) levels were significantly lower (p<0.002) on day +2 than pre-treatment values on the same day. The number of attacks reduced from 1.7+/-0.11 pretreatment to 1.2+/-0.10 at the 3rd month (p<0.001), to 1.1+/-0.06 at the 6th month (p<0.0001). The duration reduced from 25.6+/-4.42 h pretreatment to 15.5+/-4.43 h in the 3rd month (p<0.02), to 13.35+/-4.26 h in the 6th month (p<0.001). The intensity reduced from 2.4+/-0.11 pretreatment, to 1.2+/-0.10 in the 3rd month of treatment (p<0.0001), and 1.1+/-0.07 in the 6th month (p<0.0001).
authors.affiliation: Women's Headache Center, Department of Gynecology and Obstetrics, University of Turin, Via Ventimiglia 3, I-10126 Turin, Italy. gb.allais@tiscali.it
authors.forename: G
authors.initials: G
authors.lastname: Allais
authors.forename: G
authors.initials: G
authors.lastname: Bussone
authors.forename: C
authors.initials: C
authors.lastname: De Lorenzo
authors.forename: I
authors.initials: I
authors.lastname: Castagnoli Gabellari
authors.forename: M
authors.initials: M
authors.lastname: Zonca
authors.forename: O
authors.initials: O
authors.lastname: Mana
authors.forename: P
authors.initials: P
authors.lastname: Borgogno
authors.forename: G
authors.initials: G
authors.lastname: Acuto
authors.forename: C
authors.initials: C
authors.lastname: Benedetto
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000284:Administration, Oral; D000328:Adult; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage; D015232:Dinoprostone / Q000097:blood; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D008881:Migraine Disorders / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D009288:Naproxen / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D013929:Thromboxane B2; D009288:Naproxen; D015121:6-Ketoprostaglandin F1 alpha; D015232:Dinoprostone